Torrent Pharma Shares in Focus: Announced Acquisition of Controlling Stake in JB Chemicals

On June 30, 2025, Torrent Pharma shares are in focus after the company announced the acquisition of a controlling Stake in JB Chemicals & Pharmaceuticals from KKR at a valuation of ₹25,689 crore. On June 29, 2025, Torrent Pharmaceuticals Limited and global investment firm KKR announced about signing of a definitive agreement to acquire a controlling stake in J. B. Chemicals and Pharmaceuticals Ltd from KKR. The deal is based on a fully diluted equity valuation of ₹25,689 crore and will be followed by a strategic merger of the two companies.

This acquisition marks a transformative milestone for Torrent as it aims to build a future-ready, diversified healthcare platform by combining its deep presence in the chronic segment with JB Pharma’s emerging global CDMO capabilities.

Deal Structure – Two-Phase Execution

Phase 1: Strategic Acquisition

• Torrent will acquire a 46.39% stake (fully diluted basis) in JB Pharma from KKR through a Share Purchase Agreement (SPA) for a total consideration of ₹11,917 crore, at a price of ₹1,600 per share.
• A mandatory open offer will follow, where Torrent will offer to purchase up to 26% of JB Pharma’s equity from public shareholders at ₹1,639.18 per share.
• Torrent has also expressed its intention to acquire up to 2.80% of JB Pharma’s equity from certain employees, at the same price per share offered to KKR.

Phase 2: Merger

• Post-acquisition, JB Pharma will be merged with Torrent through a Scheme of Arrangement.
• Under the approved terms, JB Pharma shareholders will receive 51 shares of Torrent for every 100 shares held.

Strategic Rationale Behind the Acquisition

• Strengthens Torrent’s position in the Indian Pharmaceutical Market (IPM) with a fast-growing domestic business and top-tier chronic brands.
• Enables entry into high-potential therapeutic areas such as ophthalmology.
• Unlocks operational synergies across manufacturing, R&D, and distribution.
• Expands Torrent’s platform into the Contract Development and Manufacturing Organisation (CDMO) space, enhancing long-term global capabilities.
• Drives market consolidation and scalability in key international markets.

Also Read: MSME Loans Cross ₹40 Trillion in FY25 as Digitisation and PSL Drive Growth

Regulatory & Statutory Approvals

• The acquisition and merger are subject to customary regulatory approvals, including:
• SEBI, Stock Exchanges,
• Competition Commission of India (CCI),
• National Company Law Tribunal (NCLT),
• and other applicable statutory bodies.
• The open offer and merger process will be carried out in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Conclusion

This said acquisition of JB Chemicals reinforces Torrent’s commitment to scale sustainably and build a robust global pharmaceutical enterprise by integrating strong brand portfolios and leveraging growth platforms across geographies.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.